Shire Says Patent Settlements Didn't Delay Generic Adderall

Law360, New York (June 3, 2013, 6:30 PM EDT) -- Shire LLC on Friday urged a California federal court to throw out putative class allegations that the drug company stifled competition for Adderall XR through patent settlements and supply agreements with generic-drug makers, saying its conduct did not delay entry of a generic.

In a motion to dismiss, Shire raised a host of arguments as to why a putative antitrust class action brought against it should be tossed, including that the named plaintiff, Erin Shaffer, has no standing to challenge allegedly anti-competitive settlements Shire reached to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.